

Characterization of a Large Cluster of Influenza A(H1N1) Oseltamivir and Peramivir during the 2013-2014 Influen

Antimicrobial Agents and Chemotherapy

59, 2607-2617

DOI: 10.1128/aac.04836-14

Citation Report

#	ARTICLE	IF	CITATIONS
1	Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09 virus during the 2013â€“2014 influenza season in Mainland China. <i>Virology Journal</i> , 2015, 12, 96.	3.4	20
2	Peramivir: evidence to support the use of the first approved intravenous therapy for influenza. <i>Future Virology</i> , 2015, 10, 937-948.	1.8	4
3	Fluorescence Imaging of Virus-infected Cells with a Sialidase Imaging Probe. <i>Bunseki Kagaku</i> , 2016, 65, 689-701.	0.2	0
4	Characterization of an A (H1N1)pdm09 Virus Imported from India in March 2015. <i>Japanese Journal of Infectious Diseases</i> , 2016, 69, 83-86.	1.2	3
5	Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children. <i>Pediatrics</i> , 2016, 138, .	2.1	12
6	Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. <i>Antiviral Research</i> , 2016, 132, 170-177.	4.1	62
7	Risk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivir. <i>Infection Ecology and Epidemiology</i> , 2016, 6, 32870.	0.8	6
8	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014â€“2015. <i>Antiviral Research</i> , 2016, 132, 178-185.	4.1	155
9	Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance. <i>Antiviral Research</i> , 2016, 128, 28-35.	4.1	9
11	C646, a Novel p300/CREB-Binding Protein-Specific Inhibitor of Histone Acetyltransferase, Attenuates Influenza A Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1902-1906.	3.2	25
12	Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase. <i>Journal of Virology</i> , 2016, 90, 117-128.	3.4	47
13	Drug-Resistant and Genetic Evolutionary Analysis of Influenza Virus from Patients During the 2013 and 2014 Influenza Season in Beijing. <i>Microbial Drug Resistance</i> , 2017, 23, 253-260.	2.0	10
14	Influenza. <i>Lancet</i> , The, 2017, 390, 697-708.	13.7	550
15	Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 339-347.	9.1	27
16	Antiviral Drugs for the Treatment and Prevention of Influenza. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 318-332.	1.9	10
17	Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015â€“2016. <i>Antiviral Research</i> , 2017, 146, 12-20.	4.1	87
18	Characterization of influenza A(H1N1)pdm09 viruses isolated from Nepalese and Indian outbreak patients in early 2015. <i>Influenza and Other Respiratory Viruses</i> , 2017, 11, 399-403.	3.4	11
19	Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	33

#	ARTICLE	IF	CITATIONS
20	Community- and hospital-acquired infections with oseltamivir- and peramivir-resistant influenza A(H1N1)pdm09 viruses during the 2015â€“2016 season in Japan. <i>Virus Genes</i> , 2017, 53, 89-94.	1.6	7
21	Drug resistance in influenza A virus: the epidemiology and management. <i>Infection and Drug Resistance</i> , 2017, Volume 10, 121-134.	2.7	325
22	Identification of small molecule inhibitors for influenza a virus using in silico and in vitro approaches. <i>PLoS ONE</i> , 2017, 12, e0173582.	2.5	24
23	Data-driven interdisciplinary mathematical modelling quantitatively unveils competition dynamics of co-circulating influenza strains. <i>Journal of Translational Medicine</i> , 2017, 15, 163.	4.4	2
24	Susceptibility of Brazilian influenza A(H1N1)pdm09 viruses to neuraminidase inhibitors in the 2014â€“2016 seasons: Identification of strains bearing mutations associated with reduced inhibition profile. <i>Antiviral Research</i> , 2018, 154, 35-43.	4.1	8
25	Discovery of Bioactive Natural Products for the Treatment of Acute Respiratory Infections â€“ An Integrated Approach. <i>Planta Medica</i> , 2018, 84, 684-695.	1.3	18
27	Antiviral Activity of Peanut (<i>Arachis hypogaea</i> L.) Skin Extract Against Human Influenza Viruses. <i>Journal of Medicinal Food</i> , 2018, 21, 777-784.	1.5	33
28	InÂ-vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2016â€“17 season: Comparison with the 2010â€“11 to 2015â€“16 seasons. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 707-712.	1.7	6
29	Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016â€“2017 influenza season in Mainland China. <i>Journal of Infection and Chemotherapy</i> , 2018, 24, 729-733.	1.7	7
30	Peroxiredoxin 1 protein interacts with influenza virus ribonucleoproteins and is required for efficient virus replication. <i>Vaccine</i> , 2018, 36, 4540-4547.	3.8	2
31	Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. <i>Journal of Infectious Diseases</i> , 2020, 221, 346-355.	4.0	104
32	Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections. <i>Frontiers in Microbiology</i> , 2019, 10, 1327.	3.5	88
33	Influenza Virus Neuraminidase Structure and Functions. <i>Frontiers in Microbiology</i> , 2019, 10, 39.	3.5	280
34	Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan. <i>Influenza and Other Respiratory Viruses</i> , 2019, 13, 115-122.	3.4	12
35	Destabilization of the human REDâ€SMU1 splicing complex as a basis for host-directed antiinfluenza strategy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10968-10977.	7.1	7
36	Community spread and late season increased incidence of oseltamivirâ€resistant influenza A(H1N1) viruses in Norway 2016. <i>Influenza and Other Respiratory Viruses</i> , 2019, 13, 372-381.	3.4	11
37	Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance. <i>Current Medicinal Chemistry</i> , 2019, 25, 5115-5127.	2.4	60
38	Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study. <i>Journal of Medical Virology</i> , 2019, 91, 588-597.	5.0	23

#	ARTICLE	IF	CITATIONS
39	Differential Viral-Host Immune Interactions Associated with Oseltamivir-Resistant H275Y and Wild-Type H1N1 A(pdm09) Influenza Virus Pathogenicity. <i>Viruses</i> , 2020, 12, 794.	3.3	1
40	In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients. <i>Pathogens</i> , 2020, 9, 725.	2.8	8
41	Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility. <i>PLoS Pathogens</i> , 2020, 16, e1008592.	4.7	6
42	Antivirals Targeting the Neuraminidase. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2022, 12, a038455.	6.2	30
44	Searching for effective antiviral small molecules against influenza A virus: A patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 53-66.	5.0	11
45	Understanding the Impact of Resistance to Influenza Antivirals. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	13.6	30
47	Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance. <i>Viruses</i> , 2021, 13, 624.	3.3	29
48	Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model. <i>PLoS Pathogens</i> , 2021, 17, e1009527.	4.7	23
49	Assessment of Adherence to Post-exposure Prophylaxis with Oseltamivir in Healthcare Workers: A Retrospective Questionnaire-Based Study. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 869-874.	1.4	3
50	Structure-Guided Creation of an Anti-HA Stalk Antibody F11 Derivative That Neutralizes Both F11-Sensitive and -Resistant Influenza A(H1N1)pdm09 Viruses. <i>Viruses</i> , 2021, 13, 1733.	3.3	3
51	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. <i>Antiviral Research</i> , 2021, 194, 105158.	4.1	24
52	Resistance to Influenza Neuraminidase Inhibitors. , 2017, , 491-501.		1
53	Use of influenza antivirals in patients hospitalized in Hong Kong, 2000-2015. <i>PLoS ONE</i> , 2018, 13, e0190306.	2.5	2
54	Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. <i>Eurosurveillance</i> , 2016, 21, .	7.0	30
55	Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART. <i>Eurosurveillance</i> , 2017, 22, .	7.0	7
57	Therapeutic Approach for Seasonal Influenza and Pandemic. , 0, , .		1
58	Detection of a Peramivir-Resistant Influenza B/Yamagata-Lineage Virus Imported from Indonesia in Aichi, Japan, March 2019. <i>Japanese Journal of Infectious Diseases</i> , 2020, 73, 386-390.	1.2	1
60	Viruses Resistant to Oseltamivir or Baloxavir: What Do the Data Reveal About Resistance?. <i>Respiratory Disease Series</i> , 2021, , 221-229.	0.0	0

#	ARTICLE	IF	CITATIONS
61	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference. Antiviral Research, 2022, 197, 105227.	4.1	19
62	Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018–2020. Antiviral Research, 2022, 200, 105281.	4.1	44
63	Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution. Journal of Virology, 0, , .	3.4	0
64	Population analysis of oseltamivir-resistant variants for the rapid prediction of drug susceptibility by real-time reverse transcription polymerase chain reaction. Fukushima Journal of Medical Sciences, 2022, , .	0.4	0
65	Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model. Communications Biology, 2022, 5, .	4.4	3
66	Factors associated with viral RNA shedding and evaluation of potential viral infectivity at returning to school in influenza outpatients after treatment with baloxavir marboxil and neuraminidase inhibitors during 2013/2014–2019/2020 seasons in Japan: an observational study. BMC Infectious Diseases, 2023, 23, .	2.9	1
67	Antiviral options and therapeutics against influenza: history, latest developments and future prospects. Frontiers in Cellular and Infection Microbiology, 0, 13, .	3.9	0
68	Promises and challenges of single-domain antibodies to control influenza. Antiviral Research, 2024, 222, 105807.	4.1	0
69	Loxapine inhibits replication of hepatitis A virus in vitro and in vivo by targeting viral protein 2C. PLoS Pathogens, 2024, 20, e1012091.	4.7	0